Go to content
May 23rd 2012
Suomeksi
Text size
Home
Orion
Products and Services
Research and development
News and media
Investors
Sustainability
Careers
Orion as an investment case
Printable Fact Sheet
CEO's reviews
Operational enviroment
Market reviews
Financial objectives
Strategy
Business divisions
R&D in brief
R&D pipeline
Proprietary drugs
Outlook
Dividends
Consensus estimates
Analysts
Corporate Governance
Risk management
Calendar
Financials
Shares
Shareholder base
Investor contacts
Messages to shareholders
Home
/
Investors
/
Orion as an investment case
/
R&D in brief
/
Proprietary drugs
Print
Orion´s in-house developed proprietary drugs
Indication
Active ingredient
Launched in
dexdor
®
Intensive care sedative
Dexmedetomidine
2011
Dexdomitor®
Animal sedative
Dexmedetomidine
2007
Stalevo®
Parkinson's disease
Entacapone
2003
Simdax®
Acute decompensated heart failure
Levosimendan
2000
Precedex®
Intensive care sedative
Dexmedetomidine
1999
Comtan® & Comtess®
Parkinson's disease
Entacapone
1998
Antisedan®
Sedative-reversing drug for animals
Atipamezole
1989
Fareston®
Breast cancer
Toremifene
1988
Domitor®
Animal sedative
Medetomidine
1987
Domosedan®
Animal sedative
Detomidine
1983
Easyhaler®
Asthma and Chronic Obstructive Pulmonary Disease
Device developed by Orion for generic molecules
Since early 1990's
Updated Feb 22nd 2012
Orion Corporation, Orionintie 1A, 02200 Espoo, PO Box 65, FI-02101 Espoo, Finland
Phone +358 104261 © Copyright Orion Corporation. Company code, VAT 19992126,
Contacts
About this website
Disclaimer
Sitemap
Feedback form